标题/作者	年份
Prevalence, burden, and clinical management of migraine in China, Japan, and South Korea: a comprehensive review of the literature T Takeshima, Q Wan, Y Zhang, M Komori, S Stretton, N Rajan, T Treuer, ... The journal of headache and pain 20, 1-15	2019
Global, regional, and national burden of migraine in 204 countries and territories, 1990 to 2019 S Safiri, H Pourfathi, A Eagan, MA Mansournia, MT Khodayari, ... Pain 163 (2), e293-e309	2022
Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy–2) study S Silberstein, M Diamond, NA Hindiyeh, DM Biondi, R Cady, J Hirman, ... The journal of headache and pain 21, 1-12	2020
Comorbidities of primary headache disorders: a literature review with meta-analysis V Caponnetto, M Deodato, M Robotti, M Koutsokera, V Pozzilli, C Galati, ... The journal of headache and pain 22, 1-18	2021
Life with chronic pain during COVID-19 lockdown: the case of patients with small fibre neuropathy and chronic migraine M Consonni, A Telesca, L Grazzi, D Cazzato, G Lauria Neurological Sciences 42, 389-397	2021
Global burden of headache disorders in children and adolescents 2007–2017 M Leonardi, L Grazzi, D D’Amico, P Martelletti, E Guastafierro, C Toppo, ... International journal of environmental research and public health 18 (1), 250	2021
Migraine: a review on its history, global epidemiology, risk factors, and comorbidities P Amiri, S Kazeminasab, SA Nejadghaderi, R Mohammadinasab, ... Frontiers in neurology, 2553	2022
Burden of headache disorders in China, 1990–2017: findings from the Global Burden of Disease Study 2017 C Yao, Y Wang, L Wang, Y Liu, J Liu, J Qi, Y Lin, P Yin, M Zhou The journal of headache and pain 20 (1), 1-11	2019
Burden of migraine among Japanese patients: a cross-sectional National Health and Wellness Survey S Kikui, Y Chen, H Todaka, K Asao, K Adachi, T Takeshima The journal of headache and pain 21 (1), 1-12	2020
Alleviation of migraine symptoms by application of repetitive peripheral magnetic stimulation to myofascial trigger points of neck and shoulder muscles–a randomized trial T Renner, N Sollmann, F Heinen, L Albers, F Trepte-Freisleder, B Klose, ... Scientific Reports 10 (1), 5954	2020
Impact of galcanezumab on total pain burden: findings from phase 3 randomized, double-blind, placebo-controlled studies in patients with episodic or chronic migraine (EVOLVE-1, EVOLVE-2, and REGAIN trials) J Ailani, JS Andrews, M Rettiganti, RA Nicholson The Journal of Headache and Pain 21, 1-9	2020
Effect of migraine on pregnancy planning: insights from the American Registry for Migraine Research R Ishii, TJ Schwedt, SK Kim, G Dumkrieger, CD Chong, DW Dodick Mayo Clinic Proceedings 95 (10), 2079-2089	2020
Diagnosis, consultation, treatment, and impact of migraine in the US: Results of the OVERCOME (US) study RB Lipton, RA Nicholson, ML Reed, AB Araujo, DH Jaffe, DE Faries, ... Headache: The Journal of Head and Face Pain 62 (2), 122-140	2022
Applying a biopsychosocial model to migraine: rationale and clinical implications C Rosignoli, R Ornello, A Onofri, V Caponnetto, L Grazzi, A Raggi, ... The journal of headache and pain 23 (1), 100	2022
Acupuncture vs. pharmacological prophylaxis of migraine: a systematic review of randomized controlled trials CM Giovanardi, M Cinquini, M Aguggia, G Allais, M Campesato, S Cevoli, ... Frontiers in Neurology, 1601	2020
Pain rates in general population for the period 1991–2015 and 10-years prediction: results from a multi-continent age-period-cohort analysis D Guido, M Leonardi, B Mellor-Marsá, MV Moneta, A Sanchez-Niubo, ... The journal of headache and pain 21, 1-11	2020
Identification of work accommodations and interventions associated with work productivity in adults with migraine: A scoping review O Begasse de Dhaem, MH Gharedaghi, P Bain, G Hettie, E Loder, ... Cephalalgia 41 (6), 760-773	2021
STOP 301: A Phase 3, open‐label study of safety, tolerability, and exploratory efficacy of INP104, Precision Olfactory Delivery (POD®) of dihydroergotamine mesylate, over 24/52 weeks in acute treatment of migraine attacks in adult patients TR Smith, P Winner, SK Aurora, M Jeleva, J Hocevar‐Trnka, ... Headache: The Journal of Head and Face Pain 61 (8), 1214-1226	2021
Mapping assessments instruments for headache disorders against the ICF biopsychosocial model of health and disability D D’Amico, SJ Tepper, E Guastafierro, C Toppo, M Leonardi, L Grazzi, ... International Journal of Environmental Research and Public Health 18 (1), 246	2021
What is changing in chronic migraine treatment? An algorithm for onabotulinumtoxinA treatment by the Italian chronic migraine group S Sacco, A Russo, P Geppetti, L Grazzi, A Negro, C Tassorelli, ... Expert Review of Neurotherapeutics 20 (12), 1275-1286	2020

1 - 20

计算机程序会自动估算并确定日期和引用次数。